iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLLMichael Hallek, Thomas J. Kipps, Bruce D. Cheson et al.|Blood|2018Cited by 1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic LeukemiaRichard R. Furman, Susan O’Brien, Jeff P. Sharman et al.|New England Journal of Medicine|2014Cited by 1.7k
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III TrialJohn C. Byrd, Wojciech Jurczak, José A. García‐Marco et al.|Journal of Clinical Oncology|2021Cited by 630
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic LeukemiaWilliam G. Wierda, Anders Österborg, Thomas J. Kipps et al.|Journal of Clinical Oncology|2010Cited by 587
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma NetworkOlivier Hermine, Martin Dreyling, Eva Hoster et al.|The Lancet|2016Cited by 401